Phase 2 Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma.
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2016
At a glance
- Drugs T-cell vaccine-TVAX Biomedical (Primary) ; Interleukin-2
- Indications Glioma
- Focus Therapeutic Use
- Sponsors TVAX Biomedical
- 21 Oct 2016 Status changed from active, no longer recruiting to completed.
- 16 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Apr 2012 Additional lead trial investigators added as reported by ClinicalTrials.gov.